Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2013 Sep;114(2):241-9.
doi: 10.1007/s11060-013-1178-3. Epub 2013 Jun 16.

Perfusion and diffusion MRI combined with ¹¹C-methionine PET in the preoperative evaluation of suspected adult low-grade gliomas

Affiliations
Observational Study

Perfusion and diffusion MRI combined with ¹¹C-methionine PET in the preoperative evaluation of suspected adult low-grade gliomas

Shala Ghaderi Berntsson et al. J Neurooncol. 2013 Sep.

Abstract

Perfusion and diffusion magnetic resonance imaging (pMRI, dMRI) are valuable diagnostic tools for assessing brain tumors in the clinical setting. The aim of this study was to determine the correlation of pMRI and dMRI with ¹¹C-methionine positron emission tomography (MET PET) in suspected low-grade gliomas (LGG) prior to surgery. Twenty-four adults with suspected LGG were enrolled in an observational study and examined by MET PET, pMRI and dMRI. Histological tumor diagnosis was confirmed in 23/24 patients (18 gliomas grade II, 5 gliomas grade III). The maximum relative cerebral blood volume (rCBV(max)) and the minimum mean diffusivity (MD(min)) were measured in tumor areas with highest MET uptake (hotspot) on PET by using automated co-registration of MRI and PET scans. A clearly defined hotspot on PET was present in all 23 tumors. Regions with rCBV(max) corresponded with hotspot regions in all tumors, regions with MD(min) corresponded with hotspot regions in 20/23 tumors. The correlation between rCBV(max) (r = 0.19, P = 0.38) and MD(min) (r = -0.41, P = 0.053) with MET uptake in the hotspot was not statistically significant. Taken into account the difficulties of measuring perfusion abnormalities in non-enhancing gliomas, this study demonstrates that co-registered MET PET and pMRI facilitates the identification of regions with rCBV(max). Furthermore, the lack of a clear positive correlation between tumor metabolism in terms of MET uptake and tumor vascularity measured as rCBV(max) suggests that combined pMRI/PET provides complementary baseline imaging data in these tumors.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
a Box plots showing the distribution of rCBVmax ratios for the entire sample (n = 24). b Scatter plot showing the correlation between maximum MET uptake (HS/cortex ratio) and rCBVmax values in PET hotspot regions in all tumor samples (n = 23). Straight line, regression line, dotted lined: 95 % CI
Fig. 2
Fig. 2
a Box plots showing the distribution of MDmin values for the entire sample (n = 24). b Scatter plot showing the correlation between maximum MET uptake (HS/cortex ratio) and MDmin values (×10−3 mm2/s) in PET hotspot regions in all tumor samples (n = 23). Straight line, regression line, dotted lined: 95 % CI
Fig. 3
Fig. 3
Patient 8. Preoperative MET PET and MRI of a right-sided frontal oligodendroglioma grade II in a 31-year-old female. a MET PET shows the hotspot region of the tumor. b T2-weighted FLAIR MRI shows a high signal intensity tumor. c T1-weighted contrast-enhanced MRI shows minimal contrast enhancement in the tumor area. d DSC perfusion MRI with rCBV color map shows high perfusion in the tumor area. e DSC perfusion MRI with rCBV grey-scale map shows high perfusion in the region corresponding to the PET hotspot. The ROIs in the tumor and in the contralateral normal appearing white matter are marked. f dMRI where the MDmin value in the region corresponding to the PET hotspot is lower than MD in the medial portion of the tumor (but minimally increased compared to normal appearing contralateral white matter)

References

    1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109. doi: 10.1007/s00401-007-0243-4. - DOI - PMC - PubMed
    1. Lote K, Egeland T, Hager B, Stenwig B, Skullerud K, Berg-Johnsen J, Storm-Mathisen I, Hirschberg H. Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: a retrospective study in 379 patients. J Clin Oncol. 1997;15:3129–3140. - PubMed
    1. Soffietti R, Baumert BG, Bello L, von Deimling A, Duffau H, Frenay M, Grisold W, Grant R, Graus F, Hoang-Xuan K, Klein M, Melin B, Rees J, Siegal T, Smits A, Stupp R, Wick W. Guidelines on management of low-grade gliomas: report of an EFNS-EANO* task force. Eur J Neurol. 2010;17:1124–1133. doi: 10.1111/j.1468-1331.2010.03151.x. - DOI - PubMed
    1. Mandonnet E, Delattre JY, Tanguy ML, Swanson KR, Carpentier AF, Duffau H, Cornu P, Van Effenterre R, Alvord EC, Jr, Capelle L. Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol. 2003;53:524–528. doi: 10.1002/ana.10528. - DOI - PubMed
    1. Pallud J, Fontaine D, Duffau H, Mandonnet E, Sanai N, Taillandier L, Peruzzi P, Guillevin R, Bauchet L, Bernier V, Baron MH, Guyotat J, Capelle L. Natural history of incidental World Health Organization grade II gliomas. Ann Neurol. 2010;68:727–733. doi: 10.1002/ana.22106. - DOI - PubMed

Publication types

MeSH terms